What is Leerink Partnrs’ Forecast for BPMC FY2026 Earnings?

Blueprint Medicines Co. (NASDAQ:BPMC) – Equities researchers at Leerink Partnrs lowered their FY2026 earnings estimates for shares of Blueprint Medicines in a report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now anticipates that the biotechnology company will post earnings of $2.51 per share for the year, down from their previous forecast of $2.59. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($3.68) per share. Leerink Partnrs also issued estimates for Blueprint Medicines’ FY2027 earnings at $4.81 EPS.

Several other equities research analysts have also recently weighed in on the stock. Stephens restated an “overweight” rating and issued a $140.00 price target on shares of Blueprint Medicines in a research report on Thursday, January 2nd. Needham & Company LLC restated a “buy” rating and issued a $135.00 target price on shares of Blueprint Medicines in a report on Monday, January 13th. Piper Sandler increased their price target on shares of Blueprint Medicines from $109.00 to $119.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Wells Fargo & Company reduced their price objective on Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating on the stock in a research note on Thursday, October 31st. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $125.00 price objective on shares of Blueprint Medicines in a research note on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Blueprint Medicines presently has a consensus rating of “Moderate Buy” and an average price target of $123.72.

Blueprint Medicines Price Performance

Shares of BPMC stock opened at $109.62 on Friday. Blueprint Medicines has a 12-month low of $72.24 and a 12-month high of $121.90. The stock’s 50-day moving average price is $99.11 and its 200-day moving average price is $95.23. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09.

Institutional Investors Weigh In On Blueprint Medicines

Several institutional investors have recently bought and sold shares of BPMC. Wellington Management Group LLP boosted its position in shares of Blueprint Medicines by 22.5% in the 3rd quarter. Wellington Management Group LLP now owns 3,964,610 shares of the biotechnology company’s stock worth $366,726,000 after purchasing an additional 729,055 shares in the last quarter. State Street Corp raised its stake in Blueprint Medicines by 16.2% in the 3rd quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company’s stock worth $255,827,000 after acquiring an additional 385,818 shares during the last quarter. Geode Capital Management LLC raised its stake in Blueprint Medicines by 1.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,480,187 shares of the biotechnology company’s stock worth $136,942,000 after acquiring an additional 20,703 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Blueprint Medicines by 1.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 604,397 shares of the biotechnology company’s stock valued at $52,716,000 after purchasing an additional 7,165 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its stake in Blueprint Medicines by 161.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 496,087 shares of the biotechnology company’s stock valued at $45,888,000 after acquiring an additional 306,079 shares during the period.

Insider Activity at Blueprint Medicines

In other Blueprint Medicines news, COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $95.10, for a total value of $216,257.40. Following the transaction, the chief operating officer now owns 71,657 shares in the company, valued at $6,814,580.70. The trade was a 3.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kate Haviland sold 2,353 shares of the stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $96.60, for a total transaction of $227,299.80. Following the sale, the chief executive officer now directly owns 150,824 shares of the company’s stock, valued at approximately $14,569,598.40. The trade was a 1.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 49,851 shares of company stock valued at $4,984,696 over the last ninety days. 4.21% of the stock is owned by company insiders.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.